1. China has become the first country to approve Takeda Pharmaceutical's breakthrough narcolepsy drug Ao Ze Yue, a milestone underscoring the success of Beijing's regulatory reforms in attracting first-in-class therapies [para. 1]. The National Medical Products Administration cleared the targeted orexin tablet on July 21 under its priority review program for type 1 narcolepsy in patients aged 16 and older [para. 2]. Takeda’s application was anchored by data from global Phase III clinical trials; it was submitted in China in January 2026, ahead of submissions in the U.S. (February) and Japan (March) [para. 3]. This marks the first time a first-in-class drug with an original target, relying on a single set of global multicenter clinical data, was approved in China before anywhere else in the world [para. 5]. Takeda China President Liu Yan expressed gratitude for the accelerated review process which supports faster access to therapies for urgent unmet medical needs [para. 6].
2. Type 1 narcolepsy is a recognized chronic neurological rare disease driven by a severe loss of orexin-producing neurons, causing uncontrollable daytime sleepiness, cataplexy (sudden muscle weakness triggered by emotions), fragmented sleep, and hallucinations [para. 10][para. 8]. The disease affects an estimated 700,000 people in China, with an incidence rate of about 1 in 2,000, though large-scale epidemiological studies are lacking [para. 9]. Onset often occurs in childhood, with an average diagnosis delay of 8 to 22 years, severely impairing education, employment, and social functioning [para. 11]. Patient satisfaction with existing treatments is low: a 2024 study found nearly 40% of patients saw no significant improvement or worsening with standard medications [para. 13]. The economic burden is heavy, with annual treatment costs of 37,537 yuan for adults and 54,109 yuan for children exceeding the national per capita disposable income of 35,128 yuan [para. 14]. Previous therapies, like the first-line drug pitolisant (Wakix), focused on symptom management without addressing the core orexin deficiency [para. 15].
3. Takeda's drug operates as a highly selective oral orexin receptor 2 (OX2R) agonist, directly mimicking the function of missing orexin [para. 16]. In late-stage trials, 97% of participants reported overall symptom improvement, and the median number of days without cataplexy attacks jumped from zero at baseline to four or five days a week by the 12th week of treatment [para. 16]. While Takeda has not disclosed Chinese pricing, the existing therapy Wakix costs about 13,833 yuan annually in China. In the U.S., a health-benefit price benchmark for the new drug was estimated at $50,400 to $59,400 a year, with global peak sales potential exceeding $2 billion to $3 billion [para. 17]. Takeda is deepening its footprint in China, expecting it to become its second-largest market by 2031; it reported regional revenue of 195.1 billion yen ($1.27 billion) for the fiscal year ending March 2026 [para. 19]. This approval highlights the efficacy of China's drug regulatory overhaul, which approved a record 76 Class 1 innovative drugs in 2025, up 58.3% from the previous year. Reforms initiated in 2017 allow foreign clinical trial data to be used for domestic registration and have compressed priority review timelines to as little as 130 working days, or just 70 days for urgently needed rare-disease drugs [para. 20]. Takeda has reported that the drug holds a breakthrough therapy designation in the U.S. and is undergoing priority review there alongside standard review in Japan [para. 4]. The U.S. FDA is expected to issue its final decision on the application in the third quarter of 2026 [para. 21].
AI generated, for reference only
Sign in with Google
Sign in with Facebook
Sign in with 财新